NCT06271837 - A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors | Biotech Hunter

Enrollment

175

Participants

Timeline

Start Date

February 18, 2024

Primary Completion Date

October 30, 2025

Study Completion Date

April 1, 2027

Conditions

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Interventions

DRUG

Trastuzumab deruxtecan

Trastuzumab deruxtecan by intravenous infusion

DRUG

Bevacizumab

Bevacizumab by intravenous infusion

Trial Locations (31)

100142

RECRUITING

Research Site, Beijing

100191

RECRUITING

Research Site, Beijing

110016

RECRUITING

Research Site, Shenyang

130021

RECRUITING

Research Site, Changchun

150081

RECRUITING

Research Site, Harbin

200001

RECRUITING

Research Site, Shanghai

200011

RECRUITING

Research Site, Shanghai

200032

RECRUITING

Research Site, Shanghai

213004

WITHDRAWN

Research Site, Changzhou

221009

RECRUITING

Research Site, Xuzhou

230031

RECRUITING

Research Site, Hefei

310003

RECRUITING

Research Site, Hangzhou

310016

RECRUITING

Research Site, Hangzhou

310022

RECRUITING

Research Site, Hangzhou

322100

RECRUITING

Research Site, Dongyang

323000

RECRUITING

Research Site, Lishui

330029

RECRUITING

Research Site, Nanchang

400030

RECRUITING

Research Site, Chongqing

410013

RECRUITING

Research Site, Changsha

430022

RECRUITING

Research Site, Wuhan

450002

RECRUITING

Research Site, Zhengzhou

450008

RECRUITING

Research Site, Zhengzhou

510145

RECRUITING

Research Site, Guangzhou

510630

RECRUITING

Research Site, Guangzhou

570311

WITHDRAWN

Research Site, Haikou

610041

RECRUITING

Research Site, Chengdu

650118

RECRUITING

Research Site, Kunming

710061

RECRUITING

Research Site, Xi'an

750004

RECRUITING

Research Site, Yinchuan

Unknown

RECRUITING

Research Site, Shandong

030001

RECRUITING

Research Site, Taiyuan